A Phase I Study of BMS-986015, an Anti-KIR Monoclonal Antibody, Administered with Ipilimumab, an Anti- CTLA4 Monoclonal Antibody, in Subjects with Select Advanced Solid Tumors
|Effective start/end date||11/1/12 → 10/31/18|
- BRISTOL-MYERS SQUIBB PHARM RES
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.